Participants who were on ongoing ocrelizumab treatment on one of the following parent-studies \[Studies MN39159/CONSONANCE (NCT03523858), BN42082/MUSETTE (NCT04544436), BN42083/GAVOTTE (NCT04548999), BN44083/GLOBEAM, MN43978/CONSONANCE Ext., WA40404/O'HAND (NCT04035005), MN43964/OLERO (NCT05269004), GN41791/FENTREPID (NCT04544449), BP46016/MINTAKA, CN41144/OCARINA I-SC (NCT03972306), CN42097/OCARINA II-SC (NCT05232825)\] at the time of roll-over and who do not have access to the ocrelizumab treatment locally
The first dose of study treatment in this extension study will be received no earlier than 5 months after the last treatment in the parent study
Negative urine pregnancy test within 24 hours to first dose administered on MN45053 study treatment in participants of childbearing potential
You may not be if
Study treatment is commercially marketed in the participant's country for the participant-specific disease and is reasonably accessible to the participant
Study treatment is available via Post Trial Access Program (PTAP) in the participant's country and is accessible to the participant
Permanent premature discontinuation of study treatment for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in this extension study (if applicable)
Any condition that, in the opinion of the investigator, would interfere with the interpretation of participant safety or place the participant at high risk for treatment-related complications
Concurrent participation in any therapeutic clinical trial (other than the parent study)
Immunocompromised state
Known active malignancy or are being actively monitored for recurrence of malignancy
Known presence of other neurological disorders
Clareo Health | An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
